Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
- MHLW Proposes Salary Survey with Employees of Pharmacies
December 10, 2012
- CSIMC Nixes Industry’s Call for “Hold” on Further Price Cuts on Long-Listed Drugs
December 6, 2012
- Japan “Not Ready” for Reference Price System at the Present Time: Prof. Sakamaki of Meijo University
December 6, 2012
- CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
December 6, 2012
- MHLW Asks to Revise Precautions Section of Package Inserts for Poteligeo, Telavic
December 6, 2012
- PFSB to Initiate Epidemiological Study of Vaccination and Sudden Infant Death
December 5, 2012
- PAFSC’s 1st Committee on New Drugs Recommends Orphan Drug Designation for 2 Products Including Kyowa Kirin’s Cinacalcet
December 4, 2012
- 3 Products Including Daiichi Sankyo’s Calblock Classified as Category I
December 4, 2012
- PAFSC’s 1st Committee Recommends Approval for Factor Xa Inhibitor Apixaban
December 3, 2012
- MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
- Price Agreement Rates for JPWA, NPhA Member Companies Just 11% at End of September: Distribution Council
December 3, 2012
- Price Agreement Rate at 43.5% in September; Down 3.2 Points from 2 Years Ago: MHLW Survey
December 3, 2012
- 6 APIs Including Taiho’s Aloxi IV Infusion Bag Added to NHI Price List
December 3, 2012
- PAFSC’s 2nd Committee Recommends Approval for Allegra-Pseudoephedrine Combination Drug Dellegra
November 30, 2012
- Expert Subcommittee to Discuss New Targets for Generic Drugs at Next Meeting
November 30, 2012
- MHLW Safety Info. Calls for Caution on Pulmonary Hypertension Associated with Glivec
November 30, 2012
- FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
- Switch OTC Version of Ebastine Recommended for Approval
November 28, 2012
- BIKEN Exits New Flu Vaccine Development Project, MHLW to Invite Other Makers
November 26, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…